To test this hypothesis, we collected clinical tumor tissue and normal tissue samples from 20 glioma patients, and found that HAS2-AS1 was significantly up-regulated in tumor tissues, while similar results were obtained in glioma cell lines. This evidence concerns the gene HAS2 and central nervous system cancer.